JAK inhibitors in systemic juvenile idiopathic arthritis
ObjectiveSystemic juvenile idiopathic arthritis (SJIA) is characterized by excessive and inappropriate production of proinflammatory cytokines. Janus kinase inhibitors (JAKi) can block the downstream pathway of many cytokines. The use of JAKi in SJIA or macrophage activation syndrome (MAS) has only...
Saved in:
Main Authors: | Tingyan He (Author), Yu Xia (Author), Ying Luo (Author), Jun Yang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Canakinumab in the treatment of systemic juvenile idiopathic arthritis: a retrospective single center study in China
by: Xiaona Zhu, et al.
Published: (2024) -
Pain experience in children with juvenile idiopathic arthritis on TNFalpha-inhibitors
by: Jeppesen JH, et al.
Published: (2008) -
Juvenile Idiopathic Arthritis
by: Aleksandra Strońska, et al.
Published: (2021) -
Juvenile idiopathic arthritis
by: Krupa H Bhatt, et al.
Published: (2014) -
ADALIMUMAB IN TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: R. V. Denisova, et al.
Published: (2013)